Cancer patients treated with the targeted agent need to be closely monitored for interstitial lung disease/pneumonitis as an adverse event, say researchers reporting a new analysis.
Medscape Medical News
Lung Adverse Effects in Patients Taking Trastuzumab Deruxtecan
